CD38 is an inclusion criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain CD38 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 3 (1 open) [4].

CD38 is an inclusion criterion in 3 clinical trials for multiple myeloma, of which 3 are open and 0 are closed. Of the trials that contain CD38 status and multiple myeloma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [4].

CD38 is an inclusion criterion in 2 clinical trials for acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain CD38 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 3 (1 open) [4].

CD38 is an inclusion criterion in 2 clinical trials for chronic lymphocytic leukemia, of which 2 are open and 0 are closed. Of the trials that contain CD38 status and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

CD38 is an inclusion criterion in 1 clinical trial for angioimmunoblastic T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD38 status and angioimmunoblastic T-cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CD38 is an inclusion criterion in 1 clinical trial for follicular T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD38 status and follicular T-cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CD38 is an inclusion criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD38 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CD38 is an inclusion criterion in 1 clinical trial for peripheral T-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains CD38 status and peripheral T-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 2 (1 open) [4].

CD38 is an inclusion criterion in 1 clinical trial for plasma cell leukemia, of which 1 is open and 0 are closed. Of the trial that contains CD38 status and plasma cell leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

CD38 is an inclusion criterion in 1 clinical trial for waldenstrom macroglobulinemia, of which 1 is open and 0 are closed. Of the trial that contains CD38 status and waldenstrom macroglobulinemia as inclusion criteria, 1 is phase 3 (1 open) [4].